Abstract
We evaluated and compared the diagnostic performance of fluorescence immunoassay (FIA) and two types of serological diagnostic tests: enzyme-linked immunosorbent assay (ELISA) and immunochromatographic assay (ICA) for detection of SARS-CoV-2 antigen and antibody to diagnose COVID-19 infections. This study is aimed to analyze and compare the current status and problems of COVID-19 diagnosis and various alternative diagnostic methods that are viable. The enrolled subjects in our study population were tested with real-time polymerase chain reaction (RT-PCR). ELISA and immunochromatographic diagnostic kit were used to diagnose 362 positive and 3010 negative SARS-CoV-2 specimens, and antigen fluorescence immunoassay kit was used on 62 positive and 70 negative SARS-CoV-2 RT-PCR confirmed samples for diagnosis. As a result, categorizing by the patient symptom onset days, PCL COVID19 Total Ab EIA (ELISA) showed the sensitivity of 93.4% from 15 to 21 days, 94.2% from over 22 days, and the specificity of 99.97%. PCL COVID19 IgG/IgM Rapid Gold (ICA) had a sensitivity of 86.9%, 97.4%, and the specificity of 98.14% respectively. PCL COVID19 Ag Rapid FIA sensitivity was 93.8% from 0 to 7 days, 71.4% from 8 to 12 days and specificity was 98.57%. In conclusion, COVID-19 Ab ELISA and ICA, and COVID-19 Ag FIA are all complementary and applicable diagnostic methods to resolve the current problems of COVID-19 diagnosis.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
A total of 132 nasopharyngeal swab samples stored in VTM, including 62 positives and 72 negatives for the COVID-19, were used for the retrospective performance evaluation of the PCL COVID19 Ag Rapid FIA at 2 institutions (Dongguk university ilsan hospital and Dongguk university gyeongju hospital) under respective IRB approval (S-IRB-2020-004-04-08 and IRB-2020-01-027). A total of 105 fresh nasopharyngeal samples were evaluated prospectively by comparing the results obtained with the PCL COVID19 Ag Rapid FIA and the results obtained with RT-PCR COVID-19 (PowerChekTM2019-nCoV Real-time PCR Kit) in Chosun University Hospital under respective IRB approval (IRB-2020-02-011-002). IRB details can be found in http://www.e-irb.com/index.jsp
Funding Statement
This study was supported by the Promising IP Project Support Program (grant number: 20001089) funded by the Ministry of Trade Industry and Energy. And this study was supported by the Clinical Trial Support Program (grant number: HI18C1849) funded by the Ministry of Health and Warfare. Also, this study was supported by the Technological Innovation R&D Program (grant number: HI20C0371010120) funded by the Korea Health Industry Development Institute (KHIDI).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
S-IRB-2020-004-04-08/Dongguk university ilsan hospital IRB-2020-01-027/Dongguk university gyeongju hospital IRB-2020-02-011-002/Chosun University Hospital
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Due to confidentiality, neither the data nor the source of the data can be made available
